logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

Yum China (09987) spent HK$6.2669 million on August 25 to repurchase 17,300 shares.

date
26/08/2025
avatar
GMT Eight
Bestore China (09987) announced that on August 25, 2025, the company will invest 6.2669 million Hong Kong dollars.
YUM CHINA (09987) announced that on August 25, 2025, the company will spend 6.2669 million Hong Kong dollars to repurchase 17,300 shares.
Related Articles
HK Stock
AUSTAR (06118) released its interim performance results, with a net profit attributable to shareholders of 24.99 million yuan, an increase of 325.37% year-on-year.
HK Stock
I-CABLE COMM (01097) announces interim performance with a net loss of approximately HK$217 million, a year-on-year decrease of 14.95%.
HK Stock
Shanghai Fosun Pharmaceutical(02196): The drug registration application for Injection of Chlorhexidine Hydrochloride was accepted by the National Medical Products Administration.
AUSTAR (06118) released its interim performance results, with a net profit attributable to shareholders of 24.99 million yuan, an increase of 325.37% year-on-year.
HK Stock
I-CABLE COMM (01097) announces interim performance with a net loss of approximately HK$217 million, a year-on-year decrease of 14.95%.
HK Stock
Shanghai Fosun Pharmaceutical(02196): The drug registration application for Injection of Chlorhexidine Hydrochloride was accepted by the National Medical Products Administration.
HK Stock
RECOMMEND
Analysts Respond to Trump’s Dismissal of Fed Governor Cook as a Further Assault on Central Bank Independence
Analysts Respond to Trump’s Dismissal of Fed Governor Cook as a Further Assault on Central Bank Independence
icon
26/08/2025
U.S. Proposes Including Copper, Silicon, Silver on 2025 Critical Minerals List Amid Supply Chain Concerns
U.S. Proposes Including Copper, Silicon, Silver on 2025 Critical Minerals List Amid Supply Chain Concerns
icon
26/08/2025
Trump Vows to Slash U.S. Drug Prices by Up to 1500%, Triggering Sell-Off in Pharma Stocks
Trump Vows to Slash U.S. Drug Prices by Up to 1500%, Triggering Sell-Off in Pharma Stocks
icon
26/08/2025
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.